GPR35 and gastric cancer: The discharge of enhancers and altered activation of GPR35 leads to the growth and movement of gastric cancer cells, a notable reduction in certain immune cells (CD8 + T cells and CD4 + memory T cells), and/or infiltration (T‐cells and macrophages).